| 刘 勋,吴喜福,陈 云,迪拉拉·吐尔逊,刘燕丽.顺铂联合立体定向体部放疗治疗晚期肺癌的疗效及对患者血清CYFRA21-1、DR70和肺功能的影响[J].,2019,19(24):4695-4698 |
| 顺铂联合立体定向体部放疗治疗晚期肺癌的疗效及对患者血清CYFRA21-1、DR70和肺功能的影响 |
| Curative Efficacy of Cisplatin Combined with Stereotactic Body Radiotherapy in the Treatment of Advanced Lung Cancer and Its Effects on the Serum CYFRA21-1, DR70 and Lung Function |
| 投稿时间：2019-07-11 修订日期：2019-08-05 |
| DOI：10.13241/j.cnki.pmb.2019.24.021 |
| 中文关键词: 顺铂 立体定向体部放疗 晚期肺癌 角质蛋白21-1 DR70 肺功能 |
| 英文关键词: Cisplatin Stereotactic body radiotherapy Advanced lung cancer Keratin 21-1 DR70 Lung function |
| 基金项目:新疆维吾尔自治区自然科学基金面上项目(2011211A065) |
|
| 摘要点击次数: 597 |
| 全文下载次数: 298 |
| 中文摘要: |
| 摘要 目的：研究顺铂联合立体定向体部放疗治疗晚期肺癌的疗效及对患者血清角质蛋白21-1(CYFRA21-1)、DR70和肺功能的影响。方法：选择2016年2月到2018年2月在我院诊治的晚期肺癌患者110例，并根据随机数表法将其分为观察组(n=58)和对照组(n=52)。对照组使用常规化疗，观察组采用顺铂联合立体定向体部放疗。比较两组治疗后的疗效、治疗前后血清CYFRA21-1、DR70、第一秒最大呼气量(FEV1)、一秒用力呼气容积/用力肺活量(FEV1/FVC)、最大呼气流速峰值(PEF)及生活质量评分的变化。结果：治疗后，两组患者总有效率分别为86.21%、59.62%，观察组显著高于对照组(P＜0.05)；两组血清CYFRA21-1、DR70水平较治疗前均显著降低(P＜0.05)，且观察组以上指标明显低于对照组(P＜0.05)；两组FEV1、FEV1/FVC、PEF较治疗前均显著升高(P＜0.05)，且观察组以上指标均明显高于对照组(P＜0.05)；两组患者生活质量各项评分均较治疗前明显升高，且观察组患者生活质量各项评分均显著高于对照组(P＜0.05)。结论：顺铂联合立体定向体部放疗治疗晚期肺癌的临床疗效显著优于单用常规化疗，其可有效改善患者血清CYFRA21-1、DR70水平和肺功能。 |
| 英文摘要: |
| ABSTRACT Objective: To studyCurative efficacy ofCisplatin combined with stereotactic body radiotherapyAdvanced lung cancerand its effectsonserum Keratin 21-1 (cyfra21-1), DR70 and lung function. Methods: 110 patients with advanced lung cancer who were treated in our hospital from February 2016 to February 2018 were selected and divided into the observation group(n=58) and the control group (n=52) according to the random number table. The control group received conventional chemotherapy, while the observation group received cisplatin combined with stereotactic body radiotherapy. The changes in serum cyfra21-1, DR70, first-second maximum expiratory volume (FEV1), 1-second forced expiratory volume/forced vital capacity (FEV1 /FVC), maximum expiratory velocity peak (PEF), and quality of life score were compared between the two groups after treatment. Results: After treatment, the total effective rate of patients in the two groups was 86.21% and 59.62%, respectively, which was significantly higher in the observation group than in the control group (P<0.05). Serum levels of cyfra21-1 and DR70 in both groups were significantly lower than those before treatment(P<0.05), and the above indicators in the observation group were significantly lower than those in the control group(P<0.05). FEV1, FEV1/FVC and PEF in the two groups were significantly higher than those before treatment(P<0.05), and the above indicators, FEV1/FVC and PEF in the observation group were significantly higher than those in the control group(P<0.05). The scores of quality of life in the two groups were significantly higher than those before treatment, and the scores of quality of life in the observation group were significantly higher than those in the control group (P<0.05). Conclusion: Cisplatin combined with stereotactic body radiotherapy is significantly better than conventional chemotherapy alone in the treatment of advanced lung cancer, and can effectively improve serum cyfra21-1, DR70 levels and lung function in patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
